Back to top
more

Amylyx Pharmaceuticals (AMLX)

(Delayed Data from NSDQ)

$1.97 USD

1.97
809,228

+0.05 (2.60%)

Updated Jul 26, 2024 04:00 PM ET

Pre-Market: $2.02 +0.05 (2.54%) 9:24 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 39% (97 out of 251)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Amylyx Pharmaceuticals, Inc. (AMLX) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Amylyx Pharmaceuticals (AMLX) delivered earnings and revenue surprises of -291.67% and 21.74%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

The Zacks Analyst Blog Highlights Bristol Myers, Moderna, 2seventy bio, Amylyx Pharmaceuticals and Syros Pharmaceuticals

by Zacks Equity Research

Bristol Myers, Moderna, 2seventy bio, Amylyx Pharmaceuticals and Syros Pharmaceuticals are part of the Zacks top Analyst Blog.

Biotech Stock Roundup: MRNA Up on Vaccine Data, BMY's Updates & More News

by Zacks Equity Research

Moderna (MRNA) and Bristol Myers (BMY) are in focus on pipeline and regulatory updates.

Amylyx (AMLX) Withdraws ALS Drug, Cuts Workforce by 70%

by Zacks Equity Research

Amylyx (AMLX) makes a formal decision to remove its amyotrophic lateral sclerosis drug from the U.S. and Canadian markets. The company is expected to reduce its workforce by 70%. Its shares are trading up on the news.

Biotech Stock Roundup: AMLX, ACAD Down on Study Data, MRNA, RGLS Gain on Updates & More

by Zacks Equity Research

Amylyx Pharmaceuticals (AMLX) and Acadia Pharmaceuticals (ACAD) plunged on failure of studies.

Amylyx's (AMLX) ALS Drug Fails Pivotal Study, Stock Down 82%

by Zacks Equity Research

Following the study's failure, Amylyx (AMLX) is now uncertain whether to pull its orally administered ALS drug from the market. Management has voluntarily decided to pause all promotions of the drug.

Amylyx Pharmaceuticals, Inc. (AMLX) Misses Q4 Earnings Estimates

by Zacks Equity Research

Amylyx Pharmaceuticals, Inc. (AMLX) delivered earnings and revenue surprises of -65% and 1.93%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Will High Expenses Ail Pediatrix Medical's (MD) Q4 Earnings?

by Zacks Equity Research

Pediatrix Medical's (MD) Q4 results are likely to be hurt by an increase in practice salaries and benefits expense as well as softer patient volumes, partly offset by same-unit pricing growth.

Will a Fall in Medicaid Customers Hurt Molina's (MOH) Q4 Earnings?

by Zacks Equity Research

Molina Healthcare's (MOH) Q4 performance is likely to have been hurt by escalating medical care costs, and a decline in Medicaid and Marketplace membership, partly offset by growing Medicare premiums.

AMLX vs. NBIX: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

AMLX vs. NBIX: Which Stock Is the Better Value Option?

Is Amylyx (AMLX) Stock a Solid Choice Right Now?

by Zacks Equity Research

Amylyx (AMLX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Implied Volatility Surging for Amylyx (AMLX) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Amylyx (AMLX) stock based on the movements in the options market lately.

Amylyx Pharmaceuticals, Inc. (AMLX) Earnings Expected to Grow: What to Know Ahead of Q3 Release

by Zacks Equity Research

Amylyx Pharmaceuticals, Inc. (AMLX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Ekta Bagri headshot

Biotech Stock Roundup: ALDX, EVLO Down on Setback, SRRK Offers Updates & More

by Ekta Bagri

Regulatory and pipeline updates from Aldeyra Therapeutics (ALDX) and Scholar Rock (SRRK) are in focus in the biotech sector.

PTC Therapeutics (PTCT) Moves 5.3% Higher: Will This Strength Last?

by Zacks Equity Research

PTC Therapeutics (PTCT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Marinus Pharmaceuticals (MRNS) Soars 19.9%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Marinus Pharmaceuticals (MRNS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Amylyx Pharmaceuticals, Inc. (AMLX) Surpasses Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Amylyx Pharmaceuticals, Inc. (AMLX) delivered earnings and revenue surprises of 3,000% and 16.51%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks.com featured highlights Carnival, Amylyx Pharmaceuticals and Alkami Technology

by Zacks Equity Research

Carnival, Amylyx Pharmaceuticals and Alkami Technology have been highlighted in this Screen of The Week article.

Tirthankar Chakraborty headshot

3 Stocks Worth a Buy for Remarkable Earnings Acceleration

by Tirthankar Chakraborty

Some of the notable companies to have witnessed solid earnings acceleration as of now are Carnival (CCL), Amylyx Pharmaceuticals (AMLX) and Alkami Technology (ALKT).

Amylyx (AMLX) Down on Negative CHMP Opinion for ALS candidate

by Zacks Equity Research

Amylyx's (AMLX) shares plunge on getting a negative opinion from the Committee for Medicinal Products for Human Use for the marketing authorization of AMX0035, used to treat amyotrophic lateral sclerosis.

Amylyx Pharmaceuticals, Inc. (AMLX) Q1 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Amylyx Pharmaceuticals, Inc. (AMLX) delivered earnings and revenue surprises of 107.41% and 24.55%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Amylyx (AMLX) Doses First Patient in Wolfram Syndrome Study

by Zacks Equity Research

Amylyx (AMLX) progresses with the phase II study of pipeline candidate AMX0035 for the treatment of Wolfram syndrome as it doses the first patient.

PDS Biotech (PDSB) Up on Data From HPV-Positive Cancer Study

by Zacks Equity Research

A mid-stage study data shows that treatment with PDS Biotech's (PDSB) lead candidate in advanced HPV-positive cancer patients achieved a median overall survival of 21 months.

Minerva (NERV) Down; FDA Denies Review Schizophrenia Drug NDA

by Zacks Equity Research

Minerva (NERV) confirmed that the FDA's refuse-to-file letter on its regulatory filing, seeking approval for roluperidone, to treat symptoms of schizophrenia remains in effect.

Biohaven Pharma's (BHVN) ALS Study Fail to Meet Both Endpoints

by Zacks Equity Research

Biohaven Pharmaceuticals (BHVN) suffers a setback as verdiperstat fails to meet the primary and secondary endpoints in an ALS study.